期刊文献+

VEGF、HIF-1α、Vasohibin在子宫内膜腺癌血管生成中的作用及与预后的关系 被引量:6

THE EFFECT OF VEGF,HIF-1a,VASOHIBIN IN TUMOR ANGIOGENESIS OF ENDOMETRIOID ADEN OCARCINOMA AND ITS RELATION TO PROGNOSIS
下载PDF
导出
摘要 目的通过研究血管内皮生长因子(vascular endometrial growth factor,VEGF)、缺氧诱导因子1α(hypoxia-inducible factor-1α,HIF-1α)和vasohibin在正常子宫内膜(normal endometrium,NE)和子宫内膜样腺癌(endom-etrioid adenocarcinoma,EA)组织中的表达,探讨上述指标与间质微血管密度(microvessel density,MVD)、EA临床病理特性及预后的关系。方法采用免疫组化Envision二步法检测105例EA和20例NE组织中VEGF、HIF-1α、vasohibin和MVD的表达。分析各指标相互之间及与EA临床病理特性和预后间的关系。结果(1)EA组中,VEGF、HIF-1α和MVD的表达明显高于NE组(P<0.05),vasohibin的表达明显低于NE组(P<0.01)。(2)VEGF、HIF-1α和MVD的表达与EA的手术病理分期相关(P<0.05)。(3)在EA组,除vasohibin外,VEGF、HIF-1α和MVD三者的表达量两两间均呈正相关(P<0.05)。(4)98例有完整随访资料患者的5年生存率为87.8%,VEGF、HIF-1α及vasohibin表达阳性组与阴性组5年生存率无显著性差异;MVD高表达组5年生存率明显低于MVD低表达组(P<0.05)。结论异常增生的微血管与EA发生、发展及预后有关。VEGF、HIF-1α、vasohibin三者间动态平衡的失调促进了EA组织中的微血管生成,重建三者间的正常调节关系,刺激vasohibin的表达,可能是EA治疗的一个靶点。 Objective To study the expression of vascular endometrial growth factor (VEGF), hypoxia induced factor 1α(HIF-1α),vasohibin and microvessel density(MVD) in normal endometriums (NE) and endometrioid adenocarcinoma (EA) tissues, And to explore their relationship to the biological and pathological feathers of EA. Methods Using immunohistochemiscal Envision method, VEGF, HIF-1α, vasohibin and MVD were detected in 105 EAs and 20 NEs. The relationship between these indications and the clinicopathological features were analyzed. Results The expressions of VEGF, HIF-1α and MVD were significantly higher in EA than in NE (P〈0.05), while the expression of vasohibin was significantly lower in EA than in NE (P〈0.01). Semi-quantitative analysis revealed that VEGF, HIF-1α and MVD expressions were significantly associated with the surgical pathologic staging (P〈0.05). In the EA group, VEGF, HIF-1α and MVD had significant positive relationship between each other, while vasohibin had no significant relationship to the other three indications. The 5-year survival rate of the 98 cases of EC patients with intact followup materials was 87.8%. VEGF, HIF-1α and vasohibin were not related to the 5 year survival rate. The 5 year survival rate of paticnts with higher MVD was significantly lower than that of the group with lower MVD(P〈 0.05).Conclusion The maladjustment among the expressions of VEGF, HIF-1α and vasohibin may promot angiogenesis in EA, and may be related to the surgical pathologic staging, which might be used to anticipate the prognosis of EA. Vasohibin could be a target of the treatment of EA.
出处 《中国组织化学与细胞化学杂志》 CAS CSCD 2010年第1期43-48,共6页 Chinese Journal of Histochemistry and Cytochemistry
关键词 子宫内膜腺癌 血管内皮生长因子 缺氧诱导因子1Α VASOHIBIN 微血管密度 Endometrioid adenocarcinoma Vascular endometrial growth factor Hypoxiainducibel factor-1α Vasohibin Microvessel density
  • 相关文献

参考文献15

  • 1Merritt WM,Sood AK.Markers of angiogenesis in ovarian cancer.Dis Markers,2007,23(56):419431.
  • 2Iatrakis G,Zervoudis S,Saviolakis A,et al.Women younger than 50 years with endometrial cancer.Eur J Gynaecol Oncol,2006,27(4):399400.
  • 3Kaku T,Kamura T,Kinukawa N,et al.Angiogenesis in endometrial carcinoma.Cancer,1997,80(4):741747.
  • 4Kerbel RS.Tumor angiogenesis.N Engl J Med,2008,358(19):20392049.
  • 5Holderfield MT,Hughes CC.Crosstalk between vascular endothelial growth factor,notch,and transforming growth factorbeta in vascular morphogenesis.Circ Res,2008,102(6):637652.
  • 6Neid M,Datta K,Stephan S,et al.Role of insulin receptor substrates and protein kinase Czeta in vascular permeability factor/vascular endothelial growth factor expression in pancreatic cancer cells.J Biol Chem,2004,279(6):39413948.
  • 7Belotti D,Calcagno C,Garofalo A,et al.Vascular endothelial growth factor stimulates organspecific host matrix metalloproteinase9 expression and ovarian cancer invasion.Mol Cancer Res,2008,6(4):525534.
  • 8Ludovini V,Sidoni A,Pistola L,et al.Evaluation of the prognostic role of vascular endothelial growth factor and microvessel density in stages I and II breast cancer patients.Breast Cancer Res Treat,2003,81(2):159168.
  • 9Guo X,Philipsen S,Tanun KC.Study of the hypoxiadependent regulation of human CYGB gene.Biochem Biophys Res Commun,2007,364(1):145150.
  • 10Katavetin P,Inagi R,Miyata T,et al.Albumin suppresses vascular endothelial growth factor via alteration of hypoxiainducible factor/hypoxiaresponsive element pathway.Biochem Biophys Res Commun,2008,367(2):305310.

二级参考文献9

  • 1陈冰亚,叶大风,谢幸,陈怀增,吕卫国.卵巢上皮癌细胞中VEGF和VEGFRs的表达与STATs的活化[J].中华肿瘤杂志,2005,27(1):33-37. 被引量:17
  • 2黄带发,富伟能,尚超,徐振明,李增刚,孙开来.喉鳞癌Apaf-1基因表达及启动子区甲基化研究[J].Acta Genetica Sinica,2004,31(12):1327-1331. 被引量:8
  • 3马业罡,娄毅,赵惠儒.非小细胞肺癌组织中Apaf-1基因表达及启动子区甲基化研究[J].中华肿瘤防治杂志,2006,13(2):116-119. 被引量:5
  • 4Ahluwalia A,Hurteau J A,Bigsby R M,et al.DNA methylation in ovarian cancer.Ⅱ.Expression of DNA methyltransferas es in ovarian cancer cell lines and normal ovarian epithelial cells[J].Gynecol Oncol,2001,82 (2):299-304.
  • 5Razin A.CpG methylation,chromatin structure and gene silencing-a three-way connection[J].Embo J.1998,17(17):4905-4908.
  • 6Watanabe K,Hasegawa Y,Yamashita H,et al.Vasohbin as an endothelium-derived negative feedback regulator of angiogenesis[J].J Clin Invest,2004,114(7):898-907.
  • 7Kikuno R,Nagase T,Ishikawa K,et al.Prediction of the coding sequences of unidentified human genes ⅩⅣ.The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro[J].DNA Res,1999,6(3):197-205.
  • 8Shimizu K,Watanabe K,Yamashita H,et al.Gene regulation of a novel angiogenesis inhibitor,vasohibin,in endothelial cells[J].Biochem Biophys Res Commun,2005,327(3):700-706.
  • 9Giatromanolaki A,Sivridis E,Koukourakis M I.Tumour angiogenesis:vascular growth and survival[J].Apmis,2004,112(7-8):431-440.

共引文献4

同被引文献79

  • 1赵虹,张惊宇,徐万海,杨子超,赵庆杰.STUB1基因RNA干扰慢病毒载体的构建与鉴定[J].浙江大学学报(医学版),2010,39(6):623-627. 被引量:2
  • 2王珺,王欣彦,王敏,张淑兰.卵巢癌组织中Vasohibin基因表达与启动子区域甲基化的关系[J].中华肿瘤防治杂志,2006,13(22):1724-1727. 被引量:5
  • 3Yoshinaga K, Ito K, Moriya T, et al. Roles of intrinsic angiogenesis inhibitor, vasohibin, in cervical carcinomas [ J ]. Cancer Sei ,2011,102(2) :446-451.
  • 4Nagy VM, Buiga R, Brie I, et al. Expression of VEGF, vegfr, EGFR, cox-2 and MVD in cervical carcinoma, in relation with the response to radio-chemotherapy [J]. Rom J Morphol Embryol,2011,52( 1 ) :53-59.
  • 5Watanabe K, Hasegawa Y, Yamashita H, et al. Vasohibin as an endothehum-derived negative feedback regulator of angiogenesis [ J ]. J Clin Invest, 2004,114 ( 7 ) : 898-907.
  • 6Sato Y. Delta-like 4 and vasohibin 1: two endothelium-produced negative regulators of angiogenesis with distinctive roles[J]. Eur Cytokine Netw,2009,20(4):220-224.
  • 7Sato Y,Sonoda H. The vasohibin family:a negative regulatory system of angiogenesis genetically programmed in endothelial cells [J]. Arterioscler Thromb Vasc Biol, 2007, 27(1) :37-41.
  • 8Shibuya T, Watanabe K, Yamashita H, et al. Isolation of vasohibin-2 as a sole homologue of VEGF-indueible endothelium-derived angiogenesis inhibitor vasohibin: a comparative study on their expressions [ J ]. Arterioscler Thromb Vasc Biol, 2006,26 ( 5 ) : 1051 - 1057.
  • 9Kimura H, Miyashita H, Suzuki Y, et al. Distinctive localization and opposed roles of vasohibin-1 and vasohibin-2 in the regulation of angiogenesis [ J ]. Blood, 2009, 113 (119) :4810-4818.
  • 10Yoshinaga K, Ito K, Moriya T, et al. Expression of vasohibin as a novel endothelium-derived angiogenesis inhibitor in endometrial cancer [J]. Cancer Sci, 2008,99 ( 5 ) : 914-919.

引证文献6

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部